THE LATEST FROM RAKOVINA
Discovery in motion.
Rakovina Therapeutics Announces Warrant Exercise Incentive Program
DOWNLOAD VANCOUVER, BC, July 24, 2025 Rakovina Therapeutics Inc. (TSXV: RKV) (the "Company" or "Rakovina”) a biopharmaceutical company advancing cancer therapies through artificial intelligence (AI)-powered drug discovery is pleased to announced that, as an update to...
Rakovina Therapeutics and NanoPalm Ltd. Sign Letter of Intent to Form Joint Venture Leveraging Al-Discovered Oncology Therapies and Novel Lipid Nanoparticle Delivery Technologies
DOWNLOAD KT-3283, a duel PARP-HDAC inhibitor, to serve as first development program in NanoPalm's strategic expansion into the oncology field Vancouver, British Columbia & Riyadh, Saudi Arabia August 12, 2025 – Rakovina Therapeutics Inc. (“Rakovina” or the...
Rakovina Therapeutics Highlights Long-Standing Collaboration with the University of British Columbia and the Vancouver Prostate Centre
DOWNLOAD Vancouver, British Columbia, July 30, 2025 – Rakovina Therapeutics Inc. (“Rakovina” or the "Company") (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through AI-powered drug discovery, is pleased to highlight its...
Rakovina Therapeutics KT-5000Al Program Yields Potent ATR Inhibitor Hits in Early Screening
DOWNLOAD Compounds developed through collaboration with Variational Al show targeted activity Vancouver, British Columbia, July 23, 2025 – Rakovina Therapeutics Inc. (“Rakovina" or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing...
Rakovina Therapeutics Granted DTC Eligibility to Expand U.S. Investor Access
DOWNLOAD Vancouver, British Columbia, July 15, 2025 – Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery,...
Rakovina Therapeutics Congratulates Partner – Variational Al for Winning Life Sciences BC’s 2025 Emerging Biotech Company of the Year Award
DOWNLOAD Award Recognition underscores the importance of Al-driven drug discovery Vancouver, British Columbia, July 11, 2025 — Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation...
Rakovina Therapeutics Highlights Strength of Scientific Advisory Board Driving Innovation in Al-Enabled Oncology Drug Development
DOWNLOAD Vancouver, British Columbia, July 10, 2025 — Rakovina Therapeutics Inc. (“Rakovina” or the "Company") (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery,...
Rakovina Therapeutics Highlights Strong H1 Progress and Unveils Strategic Priorities for H2 2025
Download Vancouver, British Columbia, June 30, 2025 – Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery,...
Rakovina Therapeutics Announces Intention to Amend Debentures and Warrants
Download Vancouver, British Columbia, June 30, 2025 - Rakovina Therapeutics Inc. (TSXV: RKV) (the “Company”) announces that it will apply to the TSX Venture Exchange (the “Exchange”) to amend the terms of certain outstanding warrants and convertible...
Rakovina Therapeutics Announces Results from 2025 Annual General Meeting
Download Vancouver, British Columbia, June 25, 2025 – Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (“Rakovina” or the “Company”), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery...
Rakovina Therapeutics Announces Share Consolidation Effective Date
Download VANCOUVER, B.C., June 20, 2025 - Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE:7JO) ("Rakovina" or the "Company") is pleased to announce that the effective date for the previously announced share consolidation (the "Consolidation") will be June 24, 2025. The...
Rakovina Therapeutics to Attend BIO International Convention to Advance Strategic Partnering Opportunities
Download Vancouver, British Columbia – June 12, 2025 – Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery,...
